$20,000 in just 5 months, on a thousand shares, MAKO made members rich! Deep insight, Real Results revealed!
You could have made a whopping $20,000 in just 5 month! if you had bought only a thousand shares! Deep insight, Real Results revealed! MAKO made our members rich!
See the original post here
|
MAKO, Mako Surgical, trading at $10, could be a huge winner |
Note: PSM is an OxBridge affiliate/partner, content reprinted with permission. Editor
|
Written by Administrator |
|
Friday, 26 April 2013 10:24 |
|
MAKO Surgical (MAKO), a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specific osteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment. In addition, the company offers MAKOplasty partial knee arthroplasty (PKA) products that enable resurfacing of one or two specific diseased compartments of the joint, preserving more soft tissue and healthy bone of the knee; and MAKOplasty Total Hip Arthroplasty, a surgical solution that enables orthopedic surgeons to perform total hip arthroplasty. Further, it provides RESTORIS onlay knee implant system for patients who lack tibia sclerotic bone beds; RESTORIS MCK unicompartmental and bicompartmental knee implant system to support the tissue and bone sparing goals of MAKOplasty PKA; and RESTORIS family of hip implant systems. The company markets and sells its products through direct sales force, as well as through independent orthopedic product agents and distributors. MAKO Surgical Corp. was founded in 2004 and is headquartered in Fort Lauderdale, Florida. Sources: company, OxBridge Research, Daily Stock Deals
|
China Pharma, CPHI, Profile, Summary
China Pharma| CPHI| Profile| Summary
China Pharma, CPHI, is a specialty pharmaceutical company that develops, manufactures and markets generic and brand pharmaceutical products for both western and traditional Chinese medicines in China. Currently, the company’s main focus for its therapeutics includes CNS, cardiovascular, cerebro-vascular, wound recovery, digestive disease, and infectious diseases. Its products are sold in 30 provinces, municipalities, and autonomous regions. The Company has 16 sales offices and approximately 680 proxy agents in the whole country.
China Pharma is located in the tax-free industrial zone of Haikou, Hainan Province, with manufacturing facility of 8,000 square meters. The Company is equipped with eight GMP(Good Manufacturing Practice) certified production lines and has the capacity to produce drugs in a variety of delivery mechanisms including freeze dried(lyophilized injectables), capsules, tablets, granules, injectables, and oral fluids(suspension). The company is positioning itself to benefit from China’s rapidly growing pharmaceutical market as it expands its product portfolio.
Research & Development
China Pharma develops generic products based on market demand by combining internal product development, strategic alliances with partners and collaborations of its products and businesses. The Company targets off-patent drugs with cumulative global sales over $1billion. Under Chinese law, China Pharma is able to obtain exclusivity protection for three or more years for new generics it brings to market. The disease areas China Pharma is currently focusing on are: neurology, hyperlipidemia and cardiovascular disease, hyperglycemia and diabetes , hypertension, and infectious diseases. China Pharma has built strong research and development partnerships with the following elite institutions in China and retains the ownership rights to all resulting intellectual property of products.
Modern Manufacturing Facilities
China Pharma has scalable GMP-certified manufacturing facilities with eight different modern production lines. These facilities passed the GMP-certification when it was first introduced in 2003 and passed the latest round in 2008. The GMP-certification is repeated every five years.
In 2008 the Company invested $3.0 million to increase capacity of the dry powder line. China Pharma’s cutting edge production lines can manufacture products in the following forms of delivery: tablets; capsules; injectables; granules; oral fluids (suspension); and freeze dried (lyophilized injectables). Its production capacity fully satisfies the needs of the current portfolio.
→ -The company received GMP certification in 2003
→ - Recognized as “The Best Enterprise for Storing SARS Medicine” by Hainan Food and Drug Administration.
→ -Received national key new products certificate for Buflomedil Hydrochloride by the State Science and Technology Department, State Taxation Bureau, Ministry of Commerce, State Bureau of Quality Supervision, Inspection and Quarantine, and State Environmental Protection Bureau.
→ -Designated as key technology project in Hainan for Buflomedil Hydrochloride by
Haikou Municipality.
Source: China Pharma, OxBridge Research, Daily Stock Deals, OTC King, PSM
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks. PennyStockMonster.com is an OxBridge affiliate/partner website.
Disclosure/Disclaimer:- OxBridge Research publishes sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by OxBridge and/or its affiliates. OxBridge Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment from the company/a third party/shareholder. We receive compensation from companies for providing various IR services, including publication, advertisement,and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer, if you need assistance contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it
OxbridgeResearch.com, All Rights Reserved. Trademarks/logos are of their respective owners.
It's YOUR money - Invest WISELY TM
AXN,Aoxing Pharmaceuticals,Profile,Summary
AXN| Aoxing Pharmaceuticals | Profile | Summary
Aoxing Pharmaceuticals (AXN) is a specialty pharmaceutical company engaged in research, development, manufacturing and distribution of a variety of narcotics and pain-management products.
Aoxing was Founded in 1655, more than 300 years of heritage and deep roots in traditional and contemporary Chinese medicine.
The company has China's largest research & development facility (over 300 acre campus) and most advanced manufacturing facility for highly regulated narcotic medicines. Over 500 employees are dedicated in research and development of drugs for pain management, neurological disorders and narcotics.
Its facility is one of the few GMP facilities licensed for the manufacture of highly regulated narcotic medicines by the China State Food and Drug Administration (SFDA). It has strategic alliance partnerships with global pharmaceutical companies like the UK's Johnson Matthey Plc (LSE: JMAT), QRx Pharma (ASX: QRX) of Australia and others. Aoxing is based in China and its US office is located in Jersey City, NJ.
Source: Aoxing Pharmaceuticals, OxBridge Research, Daily Stock Deals, OTC King. PSM
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks. com is an OxBridge affiliate/partner website.
Disclosure/Disclaimer:- OxBridge Research publishes sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by OxBridge and/or its affiliates. OxBridge Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment from the company/a third party/shareholder. We receive compensation from companies for providing various IR services, including publication, advertisement,and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer, if you need assistance contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it
OxbridgeResearch.com, All Rights Reserved. Trademarks/logos are of their respective owners.
It's YOUR money - Invest WISELY TM
STEV, Stevia, could rebound, see the press release
Stevia Corp. President Discusses Expansion Plans.
Blankenbaker Delivers First in Series of 3 Articles Detailing New Revenue Streams
INDIANAPOLIS, IN--(Marketwired - Sep 10, 2013) - Stevia Corp. (OTCQB: STEV) ("Stevia Corp." or the "Company"), a farm management company focused on the economic development of stevia, the fastest growing product in the alternative sweetener sector, is pleased to offer insights regarding key aspects of its planned expansion plans.
Stevia Corp. successfully completed the first phase of its commercialization program achieving its targeted $3million revenue over the six month period ended June 30, 2013. The company is now focused on expanding its proven business model and aims to double production by the spring of 2014.
George Blankenbaker, Stevia Corp. President, comments, "Following Stevia Corp's successful harvest during the spring of 2013, our project was featured in the Vietnam Journal of Finance and a 1/2 hour nationally televised program. This recognition provided additional credibility and we are now being approached by international companies to grow for them as well as discussing potential joint ventures to operate processing factories in Vietnam. We have completed test shipments to both South Korea and Europe proving that we can meet international standards and we are preparing to enter into long-term supply agreements with buyers from both South Korea and the Netherlands."
Mr. Blankenbaker further explains, "Because Stevia Corp's model has proven to be a win-win for all parties and the farmers who participated earned higher revenues, we have the full support of the Vietnamese government and there is a waiting list of farmers who want to participate in our program. This enables us to select the best operators and maintain our high quality control standards as we expand. These key factors provide the foundation and impetus for us to rapidly expand our production to meet the growing demands of international buyers."
Blankenbaker concludes, "To successfully operate in a new market, it generally takes a few years for a company to establish itself and become well entrenched in the region while garnering the confidence and support of all parties, including the local farm communities as well as the local and national governments. But once achieved, it creates a strong foundation for rapid development. Stevia Corp has now attained this milestone and is preparing for the next phase of rapid expansion."
Further details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information visit: www.steviacorp.us.
Disclosure/Disclaimer: Stevia is a client and we have been compensated by the company and/or a third party for research/marketing/advertising services. Please read the full disclosure. Thanks
Penny Stock Monster
Feed Entries
